Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMB06MU)

Drug Name

HC-1119 Drug Info

Synonyms

Enzalutamide D3; UNII-3OKI556HC2; 3OKI556HC2; HC 1119; 1443331-82-5; CHEMBL4594421; SCHEMBL18789402; HY-70002S; CS-0019855; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide; Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)-

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 3	[1]

Cross-matching ID

PubChem CID: 71580408
CAS Number: CAS 1443331-82-5
TTD Drug ID: DMB06MU

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Androgen receptor (AR)	DTT	AR	5.955	4.868	5.902	5.567

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Prostate cancer

ICD Disease Classification

2C82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03850795) HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Hinova Pharmaceuticals.